drugs firm forecast bank job producer markets analysts consolidation teva sandoz however last francs price israel suffered protection acquired expires acquisitions bn maker month oppenheim cost based identical generics exactly branded outlook would reductions purchases pay eon estimated birgit following cuts sell call initially expected number deal told bought adding merge business shares predicted pressure may usually euros world investment cheaply statement germany worldwide rivals company compensate growth partially patent departments announced remaining work hexal producers sal unit labs rose buy able strange also drugmakers novartis chemically market convinced early overtake drug merged kuhlhoff jobs trail making see sales us drugmaker generic make newly pharmaceuticals figures said expensive swiss strong hits trading reuters acquisition necessary copy find record products offered affiliate savings development create fragmented force biggest research year